Currently, targeted therapeutics inhibit pathways dysregulated at a similar level; perhaps the most notable example being trastuzumab for HER2 positive breast cancer (upregulated in ∼ 20–30% cases)30–32. The gene discussed is ERBB2; the disease is breast carcinoma.